挪威儿童肠套叠:轮状病毒疫苗接种后的预期
挪威2014年起在严格年龄限制下引入轮状病毒疫苗,本研究基于2008-2013年全国医院登记数据验证<2岁儿童肠套叠基线发病率,并利用疫苗覆盖率和国际风险估计推算当前与扩展年龄限制下的疫苗相关肠套叠病例数,结论为放宽年龄限制仅小幅增加肠套叠病例,但被疫苗接种的获益所抵消。
要点
- 疫苗前<2岁儿童肠套叠发病率为26.7/10万儿童/年(95%CI 23.1-30.6)。
- 当前年龄限制下2016年出生队列预期1.3例疫苗相关肠套叠(95%CI 0.7-2.0)。
- 扩展年龄限制至首剂16周、第二剂24周预期增加至2.2例(95%CI 1.2-3.5)。
核心结论
- 在挪威,超出当前年龄限制接种轮状病毒疫苗会导致肠套叠病例小幅增加,但该增加被疫苗接种的获益所抵消。
研究设计与样本
- 基于2008-2013年疫苗前时期全国医院登记数据验证<2岁儿童肠套叠诊断以估计基线发病率,并利用全国疫苗覆盖数据和国际轮状病毒疫苗接种后肠套叠风险估计进行情景分析。
主要发现
- 疫苗前<2岁儿童肠套叠发病率为26.7例/年/10万儿童(95%CI 23.1-30.6),<1岁儿童为37.1例/年/10万儿童(95%CI 31.2-43.8)。
- 2016年出生队列(约60,000人)在当前年龄限制下接种,预期发生1.3例(95%CI 0.7-2.0)疫苗相关肠套叠病例。
- 若年龄限制扩展至首剂16周、第二剂24周,同一队列预期发生2.2例(95%CI 1.2-3.5)超额病例。
- 当前年龄限制下,估计每年在<5岁儿童中避免1768例轮状病毒住院;扩展年龄限制下额外避免98例轮状病毒住院。
关键数值与推荐
- 当前年龄限制:首剂在12周龄前接种,第二剂在16周龄前接种。
- 扩展年龄限制情景:首剂至16周龄,第二剂至24周龄。
- 疫苗前<2岁儿童肠套叠发病率26.7例/年/10万儿童(95%CI 23.1-30.6)。
- 疫苗前<1岁儿童肠套叠发病率37.1例/年/10万儿童(95%CI 31.2-43.8)。
临床怎么用
- 在当前年龄限制下接种轮状病毒疫苗时,疫苗相关肠套叠风险极低,且疫苗接种可显著减少轮状病毒住院。
- 若考虑放宽年龄限制以增加接种覆盖率,需权衡肠套叠病例的小幅增加与额外避免的轮状病毒住院。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To reduce the risk of vaccine-associated intussusception, rotavirus vaccination in Norway was implemented under strict age limits (the first dose given by 12 weeks of age and the second dose by 16 weeks of age) in 2014. We estimated the incidence of intussusception in children <2 years old before vaccine introduction and the number of vaccine-associated cases under current and extended age limits for vaccine administration in Norway. METHODS: To estimate the baseline incidence, we validated all diagnoses in children <2 years old registered in the national hospital registry during the pre-vaccine period of 2008-2013. Using national vaccine coverage data and international estimates of intussusception risk after rotavirus vaccination, we calculated the numbers of expected vaccine-associated intussusception cases to compare with the estimated numbers of averted rotavirus cases. Uncertainty was accounted for by several scenario analyses using current and extended age limits for vaccine administration. RESULTS: The pre-vaccine incidence of intussusception was 26.7 (95% CI 23.1-30.6) cases/year per 100,000 children <2 years old and 37.1 (95% CI 31.2-43.8) cases/year per 100,000 children <1 year old. In the 2016 birth cohort (approx. 60,000) vaccinated under the current age limits, 1.3 (95% CI 0.7-2.0) vaccine-associated intussusception cases were expected to occur. If age limits were extended to 16 weeks for the first vaccine dose and 24 weeks for the second dose, leading to more children vaccinated at an older age, 2.2 (95% CI 1.2-3.5) excess cases would be expected in the same cohort. Simultaneously, an estimated 1768 rotavirus hospitalizations/year in children <5 years old would be averted under current age limits, with 98 additional rotavirus hospitalizations averted under extended age limits. CONCLUSIONS: Administering rotavirus vaccines beyond current age limits in Norway would lead to a marginal increase in the number of intussusception cases, which would be offset by the benefits of vaccination.
引用
- Bruun T, Watle SSV, Tveteraas IH, et al. Intussusception among Norwegian children: What to expect after introduction of rotavirus vaccination? Vaccine. 2019. PMID: 31255303. doi:10.1016/j.vaccine.2019.06.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。